| 2024-04-18 | +0.1 % |
|
| 2024-04-17 | -0.27 % |
|
| 2024-04-16 | -0.8 % |
|
| 2024-04-12 | -0.92 % |
|
| 2024-04-11 | +0.67 % |
- The article discusses Halper Sadeh LLC investigating the sale of Alpine Immune Sciences, Inc. to Vertex Pharmaceuticals Incorporated, questioning whether the $65.00 per share deal is fair to Alpine shareholders in terms of obtaining the best consideration and full disclosure, potentially leading to increased consideration for shareholders and seeking additional disclosures. Vertex Pharmaceuticals stock went up last night by 0.67% due to this potential acquisition, indicating positive market sentiment towards the deal.
- Vertex Pharmaceuticals (VRTX) stock was up 0.67% last night, and the stock went up because the biotech firm Alpine Immune Sciences is to be acquired by Vertex Pharmaceuticals for about $4.9 billion in cash.
- Vertex Pharmaceuticals (VRTX) stock went up by 0.67% after it agreed to acquire Alpine Immune Sciences, a move that bolstered its portfolio in kidney diseases amidst a trend of increased deal activity in the healthcare sector.
- Vertex Pharmaceuticals (VRTX) stock went up after the company offered to acquire Alpine Immune Sciences (ALPN) in a deal valued at $4.9 billion, giving Vertex access to the biotech's immunotherapies for autoimmune and inflammatory diseases at a 38% premium to Alpine's closing price.
- Halper Sadeh LLC is investigating various companies, including Alpine Immune Sciences, for potential violations and breaches in connection to Vertex Pharmaceuticals acquiring Alpine for $65 per share, leading to an increase in Vertex Pharmaceuticals (VRTX) stock last night.
|
| 2024-04-10 | -1.71 % |
|
| 2024-04-08 | -0.6 % |
|
| 2024-04-01 | +0.59 % |
|
| 2024-03-27 | -0.27 % |
|
| 2024-03-21 | +0.87 % |
|
| 2024-03-19 | +0.93 % |
|
| 2024-03-12 | -0.49 % |
- Vertex Pharmaceuticals (VRTX) stock was down by 0.49% following a financial press release from MaxCyte, Inc., which reported an increase in operating expenses, decline in core business revenue, and net loss, leading to a negative impact on their stock.
- The article discusses that Vertex Pharmaceuticals (VRTX) stock, which was down by -0.49% last night, has been rated as "Hold" by various analysts, with three suggesting selling, seven advising to hold, and twelve recommending buying the stock, with an average target price of $417.27 per share, and a recent increase in insider selling and institutional investors reshuffling their positions likely causing the decrease in the stock value.
- Vertex Pharmaceuticals (VRTX) stock went down by -0.49% last night due to MaxCyte, Inc. reporting financial results showing declines in core business revenue, cell therapy revenue, and drug discovery revenue for the fourth quarter of 2023, impacting the overall performance of MaxCyte which had supported the recent FDA approval of CASGEVYTM by Vertex Pharmaceuticals.
- The article reports that Penserra Capital Management LLC reduced its holdings in Vertex Pharmaceuticals Incorporated by 22.5%, leading to a 0.49% decrease in the company's stock last night. The stock potentially went down due to changes in institutional investors' positions, such as Penserra Capital Management LLC selling shares and other investors making changes to their stakes in the company.
|
| 2024-03-01 | +2.86 % |
|
| 2024-02-29 | -1.46 % |
|
| 2024-02-28 | -0.92 % |
- The article discusses the dynamics of the biotech industry, emphasizing the potential returns and risks associated with investing in biotech stocks, as well as the different types of biotech companies. Vertex Pharmaceuticals (VRTX) stock went down by -0.92% last night likely due to inherent risks in the biotech sector such as regulatory hurdles, clinical trial failures, and market volatility.
- Summary: Vertex Pharmaceuticals (VRTX) stock was down -0.92% last night. The article discusses Editas Medicine's business updates, financial results, recent achievements, and upcoming events, pointing out that Vertex Pharmaceuticals provided a non-exclusive license for Cas9 and that Editas Medicine has a strong financial position with operational runway expected into 2026.
Reason for Stock Decrease: The decrease in Vertex Pharmaceuticals (VRTX) stock could be attributed to various factors, including broader market conditions, investor sentiment, company-specific news or developments, changes in the healthcare industry, regulatory issues, or simply profit-taking by investors.
- Vertex Pharmaceuticals (VRTX) stock was down last night due to the sale of 354 shares by EVP Ourania Tatsis at an average price of $425.70, sparking investor concerns.
|
| 2024-02-27 | -0.59 % |
|
| 2024-02-26 | +0.78 % |
|
| 2024-02-23 | +0.78 % |
|
| 2024-02-20 | -0.37 % |
|
| 2024-02-16 | -0.96 % |
|
| 2024-02-15 | +2.01 % |
|
| 2024-02-14 | +0.44 % |
|
| 2024-02-13 | -0.59 % |
|
| 2024-02-07 | +0.71 % |
|
| 2024-02-06 | -2.98 % |
|
| 2024-02-05 | +0.99 % |
- Vertex Pharmaceuticals (VRTX) stock went up by 0.99% after J.P. Morgan Private Wealth Advisors LLC increased its position in the company by 55.4% in the third quarter, acquiring additional shares worth $18,262,000.
- The article is about Vertex Pharmaceuticals' stock which went up by 0.99% last night, and the reason for the increase is not mentioned in the article. However, it mentions that the company's experimental triple combination cystic fibrosis treatment achieved its goals in a late-stage study.
- The article does not provide information about why Vertex Pharmaceuticals (VRTX) stock went up. It focuses on comparing the institutional ownership, valuation, risk, analyst recommendations, profitability, dividends, and earnings of Spero Therapeutics (SPRO) and Coya Therapeutics (COYA).
- Vertex Pharmaceuticals' stock went up because the company reported better-than-expected financial results, including increased revenue driven by the success of their cystic fibrosis treatment, trikafta.
- Vertex Pharmaceuticals' stock (VRTX) rose 0.99% after the company announced positive Phase 3 results for its triple regimen for cystic fibrosis, beating sales and earnings expectations for the fourth quarter and providing strong guidance for 2024 sales, in addition to noting progress in its gene-editing treatment for sickle cell disease and beta.
|
| 2024-02-02 | -2.12 % |
|
| 2024-02-01 | +0.11 % |
|
| 2024-01-30 | +2.35 % |
- Vertex Pharmaceuticals' (VRTX) stock rose by 2.35% last night following the announcement of positive results from its Phase 3 program for VX-548, a selective NaV1.8 inhibitor, for the treatment of moderate-to-severe acute pain, specifically following abdominoplasty or bunionectomy surgery.
- Vertex Pharmaceuticals' stock went up by 2.35% after the company announced positive results from late-stage trials of its experimental painkiller, VX-548, which showed significant pain reduction in post-surgery patients, bringing the company closer to developing a non-addictive alternative to opioids. Despite not performing better than opioids in the trials, analysts believe that the drug could become a blockbuster if approved by regulators, with estimated annual sales exceeding $1 billion.
- The article mentions that Vertex Pharmaceuticals (VRTX) stock went up by 2.35% last night, but it does not specify the reason for the increase.
- Vertex Pharmaceuticals (VRTX) stock went up by 2.35% after the company announced positive results from its Phase 3 program for its drug, VX-548, in the treatment of moderate-to-severe acute pain, with plans to submit a New Drug Application to the FDA by mid-2024.
- Vertex Pharmaceuticals (VRTX) stock was up 2.35% last night, but the reason for the increase is not provided in the article.
|
| 2024-01-29 | +1.31 % |
|
| 2024-01-25 | +0.56 % |
|
| 2024-01-22 | +1.17 % |
- The article discusses the potential growth prospects of CRISPR Therapeutics AG (CRSP), a biotechnology company focused on gene editing. The company's stock has been performing well, and analysts anticipate sales growth due to its promising therapies and strong financial stability. However, there are risks and challenges, such as the time it will take for revenue generation and potential regulatory hurdles. Strategic partnerships, such as with Vertex Pharmaceuticals, play a crucial role in the company's growth strategy.
- Vertex Pharmaceuticals' stock (VRTX) was up 1.17% last night, and the increase can be attributed to the company's expanding pipeline beyond cystic fibrosis (CF) treatments and positive prospects for its main revenue driver, Trikafta, as well as anticipated regulatory approvals for its cell and gene therapy treatments.
- Vertex Pharmaceuticals (VRTX) stock increased by 1.17% according to the latest report, and the rise may be attributed to various institutional investors and hedge funds buying and selling shares of the stock.
|
| 2024-01-18 | -0.18 % |
|
| 2024-01-17 | -0.85 % |
|
| 2024-01-16 | +0.94 % |
|
| 2024-01-10 | +0.65 % |
|
| 2024-01-09 | +0.45 % |
|
| 2024-01-08 | +0.63 % |
|
| 2024-01-05 | +0.08 % |
|
| 2024-01-04 | +1.32 % |
|
| 2024-01-03 | -0.05 % |
|
| 2024-01-02 | +0.99 % |
|
| 2023-12-29 | -0.58 % |
|
| 2023-12-28 | +0.3 % |
|
| 2023-12-22 | +1.15 % |
|
| 2023-12-20 | -0.72 % |
|
| 2023-12-18 | -1.47 % |
|
| 2023-12-14 | +0.38 % |
|
| 2023-12-13 | +13.23 % |
|
| 2023-12-12 | +0.4 % |
|
| 2023-12-11 | +1.75 % |
|
| 2023-12-08 | -1.07 % |
|
| 2023-12-07 | +0.14 % |
|
| 2023-12-05 | +1 % |
|
| 2023-12-01 | -1.03 % |
|
| 2023-11-29 | +1.14 % |
|
| 2023-11-28 | -0.9 % |
|
| 2023-11-24 | -0.05 % |
|
| 2023-11-22 | -0.44 % |
|
| 2023-11-17 | +2.19 % |
|
| 2023-11-16 | -1.81 % |
|
| 2023-11-14 | -2.37 % |
|
| 2023-11-09 | -2.23 % |
|
| 2023-11-08 | -0.34 % |
|
| 2023-11-07 | -1.95 % |
|
| 2023-11-06 | +2.54 % |
|
| 2023-11-02 | +1.95 % |
|
| 2023-11-01 | +1.99 % |
|
| 2023-10-31 | +1.3 % |
|
| 2023-10-25 | -1.72 % |
|
| 2023-10-20 | -0.81 % |
|
